Optometry: Open Access
Open Access

Human serum eye drops; Eye alterations; Cornea

Introduction

The human eye is a remarkable organ, allowing us to perceive the world around us through the wonders of vision. However, various factors such as age, environmental conditions, and underlying health issues can lead to eye alterations, impacting our visual acuity and overall eye health. In recent years, researchers and medical professionals have been investigating the potential of human serum eye drops as a therapeutic option to address these alterations and promote healing vision [1]. This article delves into the promising realm of human serum eye drops and their potential in alleviating eye alterations.

Cornea is mostly composed of collagen and water and is enveloped by epithelium and endothelium. These layers cooperate to ensure tissue homeostasis by providing adequate corneal transparency and reliability. After injury, corneal epithelial cells regenerate and restore the physiologic tissue architecture. In addition, a concomitant nerve regrowth and a controlled neovascularization of the damaged surface may occur. Cellular loss needs replacement by cell growth and migration [2].

In addition, a conditioned medium derived from human uterine cervical stem cells has been tested for corneal epithelial healing, and a therapeutically ocular surface medium, routinely used to culture epithelial cells, was suggested as novel eye drops for DES and PED [3].

Among these emerging therapies, the use of biologic eye drops derived from both human peripheral and umbilical cord blood serum plays a crucial role in several corneal diseases. Previous in vitro experiments showed that corneal epithelial cell morphology and cell functions are better maintained by human serum eye drops (se) than pharmaceutical tear substitutes.

Understanding human serum eye drops

Human serum eye drops are a novel approach to treating ocular conditions. These drops are derived from a patient's own blood, specifically the serum component, which is rich in essential nutrients, growth factors, and immune-modulating agents [4]. The serum is collected, processed, and formulated into eye drops, creating a personalized and biocompatible treatment option.

Nourishing nutrients: The serum is a natural source of vitamins, minerals, and antioxidants that provide essential nourishment to the eye's delicate tissues. These nutrients play a crucial role in maintaining ocular health and aiding the healing process.

Growth factors: The serum contains growth factors, such as epidermal growth factor (EGF) and fibroblast growth factor (FGF) [5], which promote cellular regeneration and tissue repair. These factors stimulate the growth of new, healthy cells to replace damaged ones.

Immune modulation: The immune-modulating properties of human serum eye drops help regulate the immune response in the eye. This can be particularly beneficial in cases where chronic inflammation or autoimmune factors contribute to eye alterations.

Lubrication and hydration: Human serum eye drops provide natural lubrication and hydration to the ocular surface, alleviating discomfort and addressing the root cause of dry eye syndrome [6].

Future directions

Several fields of medicine are focusing on a regenerative approach to treat pathologic conditions affected by insensitivity and toxic reactions to standard therapies. In this context, tissue engineering and regenerative medicine are the present and the future aim of clinical therapy, especially where traditional treatments fail or promote severe adverse events. A number of corneal conditions are often not fully managed by standard treatments and are characterized by intolerances and systemic effects. New treatments have to be considered. Subjective and objective results suggest that biologic therapies for corneal surface alterations like SE treatment could be an effective option. Indeed, the use of biologic eye drops provides the beneficial effects of vitamins, GFs, and cytokines by correcting delayed corneal healing pathways and by restoring balanced mechanisms [7]. However, the technical preparation of human serum for ocular instillation should require a well-equipped laboratory with specialized trained personnel as well as the respect of aseptic and quality procedures. In addition, methods for SE production including the proper additive and GF doses should be optimized according to well-established guidelines and standardized quality controlled protocols.

Exploring clinical evidence

Clinical trials and studies on the efficacy of human serum eye drops have shown promising results. Researchers have observed significant improvements in visual acuity, reduction in ocular inflammation, and enhanced corneal healing in patients with various eye alterations. Additionally, the personalized nature of human serum eye drops minimizes the risk of adverse reactions or rejection [8], making it a safe and well-tolerated option for many individuals.

Challenges and future directions

While human serum eye drops show immense potential, several challenges remain. The process of collecting and processing the serum can be time-consuming and costly, limiting its widespread availability.

Additionally, more extensive research is needed to understand its effectiveness in treating specific eye conditions comprehensively [9].

Looking ahead, advancements in biotechnology and medical research may pave the way for more streamlined and cost-effective methods of producing human serum eye drops [10]. Further investigations will also help identify the most suitable candidates for this personalized treatment approach.

Conclusion

Healing vision is a vital aspect of overall well-being, and human serum eye drops offer a promising avenue for addressing eye alterations. Through their nourishing nutrients, growth factors, immune modulation, and hydration properties, these drops have shown great potential in promoting ocular healing. While there are challenges to overcome, ongoing research and advancements in the field hold the key to a future where personalized human serum eye drops become a mainstream therapy for those seeking improved visual health and healing vision.

1. World Health Organization. Blindness and vision impairment prevention

Google Scholar

2. Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, et al. (2013) Vision Loss Expert Group. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health.1:339-349.

Indexed at, Google Scholar, Crossref

3. Resnikoff S, Pascolini D, Etyaale D (2004) Global data on visual impairment in the year

2002. Bull World Health Organ.82:844–851
Indexed at, Google Scholar, Crossref

4. Thapa SS, Thapa R, Paudyal I (2013) Prevalence and pattern of vitreo-retinal disorders in

 Nepal: the Bhaktapur Glaucoma Study. BMC Ophthalmol 13:9.
Indexed at, Google Scholar, Crossref

5. Hatef E, Fotouhi A, Hadhemi H, Mohammad K, Jalali KH (2008) Prevalence of retinal diseases and their pattern in Tehran: The Tehran eye study. Retina 28: 755-762.

Indexed at, Google Scholar, Crossref

6. Nirmalan PK, Katz J, Robin A (2004) Prevalence of vitreoretinal disorders in a rural population of southern India. Arch Ophthalmol 122:581–586.

Indexed at, Google Scholar, Crossref

7. Rai BB, Morley MG, Bernstein PS, Maddess T (2020) Pattern of vitreo-retinal diseases at the national referral hospital in Bhutan: a retrospective, hospital-based study. BMC Ophthalmol.20:51.

Indexed at, Google Scholar, Crossref

8. Chauhan A, Chaudhary KP, Rajput GC (2014) Pattern of retinal diseases in hilly terrain of Himachal Pradesh, India. Int Eye Sci 14:2114–2118.

Google Scholar

9. Saunier V, Merle BMJ, Delyfer MN (2018) Incidence of and risk factors associated with age-related macular degeneration: four-year follow-up from the ALIENOR study. JAMA Ophthalmol 136:473-481

Indexed at, Google Scholar, Crossref

10. Hallak JA, de Sisternes L, Osborne A, Yaspan B, Rubin DL, et al.(2019) Imaging, Genetic, and Demographic Factors Associated With Conversion to Neovascular Age-Related Macular Degeneration: Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol.137:738-744

Indexed at, Google Scholar, Crossref